CagriSema vs SLU-PP-332
A side-by-side research comparison of CagriSema and SLU-PP-332 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | SLU-PP-332 |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | SLU-PP-332 (ERR Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research compound (preclinical) |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. |
| Molecular weight | Combination product | ~426 Da (small molecule, not a peptide) |
| Half-life | 7 days (both components) | Not well characterized in humans |
| Bioavailability | High (SubQ) | Studied via injection in animals; oral activity under investigation |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | No established human dose |
| Frequency | Once weekly | Unknown |
| Route | Subcutaneous | Injection (preclinical) |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Related comparisons
Research and educational reference only. Not medical advice.